Clinical Trial Finder

Inclusion Criteria:

• - Diagnosis: Patients with histologically verified medulloblastoma with recurrence or progression involving anywhere in the brain and/or spine.

• - Patient must have either measurable or evaluable tumor as assessed by MRI of the brain and total spine.

• - An implanted catheter in the fourth ventricle or posterior fossa tumor cavity attached to a ventricular access device or agreement to have one placed.

• - A minimum of 7 days between last dose of systemic chemotherapy and/or radiation therapy and first infusion of chemotherapy into fourth ventricle.

• - Life expectancy of at least 12 weeks in the opinion of the principal investigator.

• - Lansky score of 50 or greater if ≤16 years of age or Karnofsky score of 50 or greater if > 16 years of age.

• - Existing neurological deficits must have been stable for a minimum of 1 week prior to study enrollment.

• - Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy.

• - Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) ≥ 500/µL, platelet count ≥ 50,000/µL (transfusion independent), and hemoglobin ≥ 9.0 gm/dL (may receive red blood cells(RBC) transfusions) - Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent.

• - Patient with prolonged QT interval on screening EKG will need cardiology consultation prior to enrollment.

• - Patients with abnormal liver function tests (ALT, Aspartate Aminotransferase(AST),or total bilirubin) will need gastroenterology consultation prior to enrollment.

Exclusion Criteria:

• - Enrolled in another treatment protocol.

• - Has received another investigational or chemotherapy agent or radiation therapy within 7 days prior to intraventricular chemotherapy infusions.

• - Evidence of untreated infection.

Arms

Interventions